Kostantinos (Kostas) Kosmatopoulos

Title: The Innovative Contributions of Kostantinos (Kostas) Kosmatopoulos

Introduction

Kostantinos (Kostas) Kosmatopoulos is a notable inventor based in Paris, France. He has made significant contributions to the field of cancer immunotherapy, holding a total of 6 patents. His work focuses on developing innovative vaccine strategies that target specific tumor antigens, aiming to improve treatment outcomes for patients.

Latest Patents

One of his latest patents involves the use of a vaccine targeting a cryptic tert epitope for treating cancer in HLA-A*0201-positive patients with non-immunogenic tumors expressing tert. This invention utilizes a tumor vaccine composed of two peptides of nine amino acids, specifically the WT cryptic TERT572 and its optimized variant TERT572Y. Another significant patent pertains to the identification, optimization, and use of shared HLA-B*0702 epitopes for immunotherapy. This invention provides novel methods for efficiently treating patients with the HLA-B*0702 phenotype, focusing on peptides that can trigger cytotoxic responses against multiple antigens from a single multigenic family.

Career Highlights

Throughout his career, Kostas has worked with several prominent companies in the biotechnology sector, including Vaxon Biotech and Kriptic Pharmaceuticals Limited. His expertise in immunotherapy and vaccine development has positioned him as a key figure in advancing cancer treatment methodologies.

Collaborations

Kostas has collaborated with notable professionals in his field, including Jeanne Menez-Jamet and Stéphanie Graff-Dubois. These collaborations have further enriched his research and contributed to the success of his innovative projects.

Conclusion

Kostantinos (Kostas) Kosmatopoulos is a pioneering inventor whose work in cancer immunotherapy is making a significant impact. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient care.